Mouse BMD Quantitative Trait Loci Show Improved Concordance With Human Genome-wide Association Loci When Recalculated on a New, Common Mouse Genetic Map by Ackert-Bicknell, Cheryl L et al.
Mouse BMD Quantitative Trait Loci Show Improved
Concordance With Human Genome-wide Association
Loci When Recalculated on a New, Common Mouse
Genetic Map
Cheryl L Ackert-Bicknell,
1 David Karasik,
2 Qian Li,
1 Randy V Smith,
1 Yi-Hsiang Hsu,
2 Gary A Churchill,
1
Beverly J Paigen,
1 and Shirng-Wern Tsaih
1
1The Jackson Laboratory, Bar Harbor, ME, USA
2Hebrew SeniorLife and Harvard Medical School, Boston, MA, USA
ABSTRACT
Bone mineral density (BMD) is a heritable trait, and in mice, over 100 quantitative trait loci (QTLs) have been reported, but candidate
genes have been identified for only a small percentage. Persistent errors in the mouse genetic map have negatively affected QTL
localization, spurring the development of a new, corrected map. In this study, QTLs for BMD were remapped in 11 archival mouse data
sets using this new genetic map. Since these QTLs all were mapped in a comparable way, direct comparisons of QTLs for concordance
would be valid. We then compared human genome-wide association study (GWAS) BMD loci with the mouse QTLs. We found that 26 of
the 28 human GWAS loci examined were located within the confidence interval of a mouse QTL. Furthermore, 14 of the GWAS loci
mapped to within 3 cM of a mouse QTL peak. Lastly, we demonstrated that these newly remapped mouse QTLs can substantiate a
candidate gene for a human GWAS locus, for which the peak single-nucleotide polymorphism (SNP) fell in an intergenic region.
Specifically, we suggest that MEF2C (human chromosome 5, mouse chromosome 13) should be considered a candidate gene for the
genetic regulation of BMD. In conclusion, use of the new mouse genetic map has improved the localization of mouse BMD QTLs, and
these remapped QTLs show high concordance with human GWAS loci. We believe that this is an opportune time for a renewed effort by
the genetics community to identify the causal variants regulating BMD using a synergistic mouse-human approach.  2010 American
Society for Bone and Mineral Research.
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Introduction
C
urrently, 43.7 million Americans over the age of 50 years are
predicted to already have or be at serious risk of developing
osteoporosis.
(1) Bone mineral density (BMD) is a clinically
measurable predictor of future fracture risk, and studies in
humans have demonstrated that over 80% of the variance in
peak bone mass is due to heritable factors.
(2) Human genome-
wide association studies (GWAS) have identified several
significant loci for BMD, but collectively, the genome-wide
significant (GWS) loci identified to date explain only a small
portion of the variance in BMD.
(3) This suggests that many more
loci may be involved in the regulation of BMD.
(4) Furthermore,
identification of a locus by GWAS does not necessarily equal
identification of the causal variant/gene.
(5) For other complex
phenotypes, such as high-density lipoprotein (HDL) cholesterol,
it has been demonstrated that genetic studies in mice are very
powerful tools for candidate gene identification in humans.
(6)
To date, well over 100 quantitative trait loci (QTLs) mapped in
mice for BMD are reported in the literature, but few of the
underlying genes have been identified.
(7)
The QTLs found in single-cross analyses typically have
confidence intervals (CIs) extending for 20 to 40 cM, encom-
passing hundreds of genes,
(8) Two powerful techniques have
been developed to combine information from multiple QTLs
to narrow the list of candidate genes: combined cross-analysis
and block haplotyping. Combined cross-analysis uses two or
more crosses for which a QTL for the same phenotype has been
mapped at the same or similar genetic location. The data from
these crosses are merged, and the QTLs are remapped.
(8) This
technique improves both the power for QTL detection and QTL
resolution.
(9,10) Block haplotyping is the second method used to
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1808narrow QTLs. When a QTL is found, it is safe to assume that
the gene responsible for the QTL will not be located where the
two parental strains share a haplotype (ie, are genetically
identical).
(11) Instead, the gene will be located in a haplotype
block for which the two strains are dissimilar. When a QTL has
been identified in two distinct crosses at the same location,
it therefore can be assumed that the gene will be in a region
where the two parental strains carrying the high allele share a
haplotype, where the two parental strains carrying the low allele
share a haplotype, and where the high-allele and low-allele
haplotypes are different. This block haplotyping approach can
be used to reduce the size of the QTL region by up to 90%.
(9,11,12)
Both these techniques rely on knowing what other QTLs
have been mapped for a given phenotype and exactly where
those QTLs are. Unfortunately, obtaining complete and accurate
information about bone QTLs mapped in mice is not as
straightforward as a simple literature search. The type and level
of information published about the QTLs have improved along
with the mapping techniques. Often, suggestive QTLs (ie, QTLs
for which the significance level was above background but did
not reach a p<.05 significance) are not reported for fear of
‘‘cluttering the literature.’’ Suggestive QTLs, nonetheless, can be
used for both block haplotyping and combined cross-analysis to
increase the power of detection and narrow the QTL. Pertinent
information for a given QTL may never have been reported.
Specifically, CIs or allele effects, both of which are required for
block haplotyping, are often missing. Also, the marker closest to
the peak may have been reported instead of the location of the
actual QTL peak location. Depending on the density of the
markersusedinactuallygenotypingthecross,themarkerclosest
to the peak and the actual peak of the QTL could be several cM
apart. The algorithm used for QTL mapping often varies widely
among studies, and different covariates such as body weight
may or may not have been incorporated into the model, making
absolute comparison of a pair of QTLs difficult. The last factor
hindering the comparison of QTLs found in different studies is
the fact that there are problems with the standard mouse
genetic map.
The current standard genetic map for the mouse is curated
and maintained by the Mouse Genome Informatics (MGI) Group
at the Jackson Laboratory (www.informatics.jax.org/).
(13) This
map is based largely on information obtained from two small
mouse crosses.
(14,15) The traditional genetic map is updated on
an annual basis and has improved over time,
(16) but it still retains
historical errors related to marker order and chromosome
assignment.
(17) Mapping QTLs requires accurate genetic map
information for both the relative order of markers and the
distances between them. Recently, Shifman and colleagues
published a new genetic map based on a large heterogeneous
stock population.
(18) A total of 7080 standard simple-sequence-
length polymorphism (SSLP) markers were integrated to this
single-nucleotide polymorphism (SNP)–based map, generating
a corrected mouse genetic map.
(17) This new map resolves
inconsistencies between the physical and genetic maps and
provides highly accurate genetic distances. A recent mapping
study, in which the new and traditional genetic maps were
compared, suggests that up to 20% of published QTLs may have
been mislocalized owing to marker order and positioning errors
intheoldgeneticmap.
(17)Inthisstudywehavecollectedtheraw
data from the majority of the original mouse crosses for bone
phenotypes. The QTLs for the BMD phenotypes measured in
each cross were remapped using the new mouse genetic map.
Lastly, the mouse QTL peak locations were compared with
human BMD GWAS loci.
Materials and Methods
Identification of mapping-cross data sets
First, a literature search to identify published reports of mouse
BMD QTLs was done using the following key words: BMD, mouse,
QTL, bone mineral density, mapping, and/or loci. Second, the
Mouse Genome Informatics Database (www.informatics.jax.org/)
was searched for bone-related QTLs using the ‘‘Genes and
Markers Query’’ form. Specifically, this database was searched
using the keyword bone in the ‘‘Gene/Marker Symbol/Name’’
field, QTL in the ‘‘Type’’ field, and Any in the ‘‘Chromosome’’ field;
the‘‘NoLimit’’boxwascheckedundertheheadingof‘‘Maximum
Returned.’’ QTLs for non-BMD phenotypes, such as ‘‘bone
marrow graft rejection’’ and ‘‘bone area,’’ were struck from the
returned list. The cross in which each BMD QTL was mapped was
identified and compared with the list of crosses identified by
conventional literature search. In short, the result was a list of
mouse mapping crosses in which BMD QTLs were mapped
regardless of the method used to measure density.
Main-effects QTL mapping
Map positions for the markers for all data sets were updated to
the new mouse genetic map using a mouse map converter tool
found at http://cdg.jax.org. All QTL analyses were done using the
R/qtl software package
(19) (R Version 2.6.2, qtl Library Version
1.09-43, www.rqtl.org/). Phenotypic outliers were removed prior
to QTL analyses. In all cases, the phenotype trait data were
transformed using the van der Waerden normal score method to
correct for any skewing of the data.
(20) Since we did not generate
the original data, we performed rigorous quality-control analysis
of the genotyping data prior to QTL mapping. First, errors in
genotyping were identified by comparing the ‘‘User imputed
marker positions’’ (ie, marker positions in cM from the new
mouse genetic map) with the cross-calculated genetic position,
as calculated in a cross-specific manner, using R/qtl. When the
cross-calculated genetic positions were in large disagreement
with marker positions input by the user, possible errors inmarker
ordering were examined. Second, the recombination fraction for
all possible pairs of markers for a given cross were calculated
using the est.rf function in R/qtl. The recombination fractions
then were plotted using the plot.rf function in R/qtl. Markers
exhibiting low recombination fraction/high LOD with non-
adjacent markers (ie, markers at the opposite end of the
same chromosome or with a marker on a completely different
chromosome) were considered to be in error. When marker
errors could not be resolved, the marker was deleted. A single-
locus mainscan for QTL was performed, and LOD scores were
calculated at 2-cM intervals across the genome using the ‘‘imp,’’
or imputation, method in R/qtl for all data sets except the
B6xC3H data set from Farber and colleagues.
(21) The data set
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markers, with nomissinggenotypes. Because ofthis highdensity
in genotyping data, marker regression was run for the main
QTL scan for this one data set. The LOD thresholds for significant
and suggestive QTLs were determined in a cross-specific
manner based on 1000 permutations of the data.
(22) A QTL
was considered to be suggestive if the LOD score exceeded
the p<.63 threshold and significant if it exceeded the p<.05
threshold. These thresholds were chosen because they are the
widely accepted cutoffs for suggestive and significant QTLs.
(23)
The goal of this analysis was to identify main-effect QTLs;
therefore, no pairwise/interactive genome scans were run.
For 5 of the 12 crosses, data were available for both male and
female mice (Table 1). To account for the average differences
between the males and females, we carried out scans using sex
as an additive covariate. To identify sex-dependent QTL effects,
we carried out additional scans using sex as an interactive
covariate and computed the differences in LOD scores between
these two scans (ie, the DLOD).
(24) The interactive scan model
identified the most likely position of the sex-specific QTLs.
Calculating the DLOD score at the peak position is the secondary
test for the QTL-by-sex interaction.
(24) This secondary test is
carried out with no adjustment for multiple testing, and the
threshold, based on the usual chi-square distribution of the
likelihood ratio, is 2.0 on the LOD scale. The sex specificity of
these QTLs then was confirmed using the addqtl function in R/qtl
by including ‘‘Qi:sex’’in the main effected model, where iwas the
location of the putative sex-specific QTL. The cross generated
by Farber and colleagues was bred in a reciprocal fashion
(ie, B6 C3H F1 C3H B6 F1), and therefore, cross-direction
also was considered in the main effects model. Similar to the
sex covariate, the strain of paternal grandmother (pgm)
for each mouse was considered as both an additive and
interactive covariate. The DLOD was calculated to identify
potential ‘‘pgm-specific QTLs.’’ The covariate of ‘‘sex:pgm’’ also
was included in the model to look for QTLs that were contingent
on both cross-direction and gender. The pgm specificity of
these QTLs was confirmed using the addqtl function, including
‘‘Qi:pgm’’ in the model, as was described for sex-specific QTLs.
Comparison with human BMD genetic loci
Human BMD genome-wide significant loci from GWAS studies
were identified from the literature.
(3,25–27) For each GWS locus,
dbSNP (Build 130) was used to determine the genomic
coordinates for the most significant SNP and 500 bp surrounding
the SNP. These human genomic coordinates were lifted over to
the mouse genome (Build 37) using the ‘‘Batch Coordinate
Conversion’’ tool found at http://genome.ucsc.edu/index.html.
If the Batch Coordinate Conversion lift-over was unsuccessful,
the region surrounding the SNP was examined in the
human genome browser window. The interval examined was
Table 1. Description of the Cross Data Sets
Cross (reference) Number of mice
a Phenotype(s) examined Age (weeks) Notes
b
B6 129
(35) 291 (F) Whole-body aBMD 20 Fed HF for last 14 weeks
Vertebral aBMD
B6 C3H
(34,54) 998 (F) Femoral vBMD 16
Vertebral vBMD
B6 C3H
(29) 145 (F) Femoral aBMD 35 Fed HF for last 14 weeks
164 (M)
B6 CASA
(52) 184 (F) Whole-body aBMD 11
185 (M)
B6 CAST
(36) 711 (F) Femoral vBMD 16 Selectively genotyped
B6 DBA
(55–57) 595 (F) Whole-body aBMD 16 Data available for 2 ages, only used
younger mice in this analysis
391 (M) Femoral aBMD
B6 DBA
(30) 110 (F) Femoral aBMD 68 Fed HF for last 16 weeks
Femoral vBMD
Midshaft vBMD
MRL CAST
(39) 170 (F) Whole-body aBMD 7
157 (M) Midshaft vBMD
MRL SJL
(32,33) 621 (F) Whole-body aBMD 7
Midshaft vBMD
NZB RF
(31) 661 (F) Femoral vBMD 10
Femoral cortical vBMD
Midshaft vBMD
Midshaft cortical vBMD
NZB SM
(58) 143 (F) Whole-body aBMD 24 Fed HF for last 16 weeks
124 (M) Vertebral aBMD
aF¼female; M¼male.
bHF¼high-fat diet.
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was identified on the ‘‘Mouse (July 2007/mm
9) Alignment Net’’
track. The coordinates in the mouse genome for this conserved
track were extracted. All mouse genomic coordinates then were
converted to the cM position using the ‘‘Mouse Map Conversion
Tool’’ found at http://cgd.jax.org/.
We wished to confirm that lifting over the genomic
coordinates of the most significant SNPs from human to mouse
meant moving over to the same gene ‘‘neighborhood’’ in both
humanandmouse.Therefore,weidentifiedthemousegenethat
was homologous to the human gene closest to the GWS peak.
Wethenidentifiedthechromosome,startingMbandendingMb,
in the mouse for that gene. In all cases, we found that the
coordinates for the peak SNP, as lifted over into mouse, were
located in close proximity to the identified homologous mouse
gene. This indicated that we were correctly moving the human
GWAS peaks over to a similar gene neighborhood in the mouse.
Block haplotyping
Block haplotyping was done using the strain-comparison tool
located at http://cgd.jax.org/. Specifically, the ‘‘Imputed Diversity
Array, Build 37’’ SNP set was used. The following comparison
expression was built:
ðMRL=MpJ ¼ C57BL=6JÞ 6¼ð SJL=J ¼ CASA=RkJÞ (1)
All blocks consisting of at least one SNP extending for at least
1 bp were extracted. The results for all of chromosome 13 were
downloaded, and any blocks outside our region of interest were
deleted. The start and end positions for all mouse Refseq genes
found in our region of interest were downloaded from the UCSC
genome browser (http://genome.ucsc.edu). A gene was con-
sidered a candidate if a haplotype block was found anywhere
between the genomic start and end positions for that gene.
Since CASA/RkJ is a wild-derived strain, we were concerned that
we were inappropriately removing genes from the candidate
list by forcing SJL/J to equal CASA/RkJ in the haplotype block
definition. We then repeated this exercise without the SJL/J
equal to the CASA/RkJ term.
Results
Eligible data sets for reanalysis
Collectively, 15 mouse-mapping crosses in which BMD QTLs had
been mapped were identified. The corresponding author and
senior author for the first paper describing the data set were
contacted and asked if they were willing to provide complete
genotypeandphenotypedatafortheirdatasetforamouseBMD
QTL remapping project. Authors were asked separately if they
were willing to deposit their data set into a public QTL data
repository,suchastheCenterforGenomeDynamic’sQTLarchive
(http://cgd.jax.org/nav/qtlarchive1.shtml). Intotal, 13 data sets of
the 15 requested were received. No response was received from
one set of authors, and one data set was not available for
analysis. We decided not to include two data sets that were
received for this project because they were too small and/or
incomplete to do accurate mapping. The first of these two
crosses
(28) did not have genotype information available for every
chromosome and had very low marker density (one to three
markers per chromosome) for other chromosomes. The second
of these
(28) had only had 51 mice with genotype information
available, making this data set underpowered for QTL detection
in the algorithm we used. In sum, 11 data sets were used for this
mouse BMD QTL recalculation project (Table 1).
Overview of QTLs mapped
Intotal,155primaryQTLswereidentifiedinthe11 datasetsused
for analysis, as is presented in Table 2: 86 QTLs for femoral BMD,
34 for vertebral BMD, and 35 for whole-body areal BMD (aBMD).
At least one QTL for BMD was identified for each chromosome,
with the exception of the Y chromosome (Fig. 1). We identified
six QTLsthat werespecific tomales,six QTLs thatwerespecific to
females, and 47 QTLs that were not sex specific. An additional 96
QTLs were mapped in crosses for which only data from female
mice were available, and thus no determination of sex specificity
could be made. One QTL, on chromosome 7, mapped in the
B6 C3H data set from Farber and colleagues,
(29) was found to
be cross-direction-specific, indicating a potential parent-of-
origin effect.
For both the B6 DBA cross generated by Drake and
colleagues
(30) and the NZB RF cross,
(31) multiple femoral
BMD phenotypes were measured. In the B6 DBA cross by
Drake and colleagues, phenotypic data were available for
femoral aBMD, femoral volumetric BMD (vBMD), and midshaft
vBMD.IntheNZB RFdataset,fourphenotypesweremeasured:
midshaft vBMD, midshaft cortical vBMD, totalfemoral vBMD, and
total femoral cortical vBMD. In some instances, QTLs with the
same peaklocation andsimilar CIs werefound for more than one
femoral phenotype within a single cross. Since there also were
unique QTLs for each phenotype, we have presented all QTLs
identified for BMD, regardless of type, mapped in these two
data sets.
Comparison with human GWAS loci
To date, 20 substantiated (ie, p<5 10
 8) genome-wide
significant (GWS) loci for BMD have been identified in a large
meta-analysis of five independent GWAS (the GEFOS Consor-
tium).
(3) We compared the locations of these 20 loci with the
mouse QTLs (Table 3). We found that 16 of the 20 most
significant GWS markers fell within the CI of a mouse QTL. Two of
the GWS loci that did not appear, at first examination, to fall
within a mouse QTL were very interesting. The first of these,
located on humanchromosome 3 at41 Mb,mouse chromosome
9 at 120.7 Mb (72 cM), is only 0.5 cM away from the peak of an
acentric QTL mapped in NZB RF (peak location of 71.49 cM).
The second of these, located on human chromosome 6 at 152
Mb,mousechromosome10at5.7Mb(2.1cM),isnearthepeakof
an acentric QTL, 0.4 cM away, mapped in B6 DBA (peak
location of 2.53 cM). In both these cases, the mouse QTL peak
location is at or near the last/first marker genotyped in the cross
for that chromosome. There are no other informative flanking
markers by which to judge if the QTLs are truly acentric. Thus
we consider these two human GWS loci likely to be within a
mouse QTL. Nine of the human GWS loci are located with 2 cM of
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Chr
Peak
(cM)
LOD
score
Confidence
interval (cM) Peak marker Phenotype
a
High
allele
Cross
(reference)
Gender
specific
b
1 51.66 2.13 1.66–97.30 D1Mit191 Femur aBMD B6 B6 DB
(56,57) F&M
1 62.50 27.50 58.50–64.50 D1Mit14 Femur vBMD C3H B6 C3H
(34) F( M? )
1 63.84 3.23 34.46–94.35 D1Mit346 Whole-body aBMD MRL MRL SJL
(32,33) F( M? )
1 69.01 3.41 48.81–89.51 rs3701299 Femur aBMD C3H B6 C3H
(29) F&M
1 72.50 14.04 66.50–76.50 D1Mit14 Vertebral vBMD C3H B6 C3H
(34) F( M? )
1 74.46 2.32 46.46–92.46 D1Mit111 Femoral midcort vBMD NZB NZB RF
(31) F( M? )
1 74.46 3.51 44.46–84.46 D1Mit111 Femoral mid vBMD NZB NZB RF
(31) F( M? )
1 76.12 10.96 70.12–78.12 D1Mit15 Femur vBMD CAST B6 CAST
(36) F( M? )
1 76.46 2.67 52.46–86.46 D1Mit111 Femur vBMD NZB NZB RF
(31) F( M? )
1 76.73 4.06 70.08–94.08 D1Mit540.1 Whole-body aBMD CASA B6 CASA
(52) F&M
1 80.08 3.13 18.08–97.04 D1Mit115 Vertebral aBMD 129 B6 129
(59) F( M? )
1 87.66 4.49 79.66–91.66 D1Mit291 Whole-body aBMD DBA B6 DBA
(56,57) F&M
1 90.08 3.96 78.08–96.08 D1Mit406 Whole-body aBMD 129 B6 129
(35) F( M? )
1 90.46 5.87 82.46–94.35 D1Mit291 Femoral mid vBMD MRL MRL SJL
(32,33) F( M? )
2 2.23 2.62 2.23–84.23 D2Mit1 Whole-body aBMD MRL MRL CAST
(39) F&M
2 3.62 3.64 3.62–14.54 rs3676722 Femur aBMD B6 B6 C3H
(29) M
2 40.90 4.12 30.90–46.90 D2Mit205 Whole-body aBMD B6 B6 CASA
(52) F&M
2 44.70 8.28 34.70–58.70 D2Mit91 Whole-body aBMD DBA B6 DBA
(56,57) F
2 57.81 4.32 47.81–62.49 D2Mit62 Whole-body aBMD MRL MRL SJL
(32,33) F( M? )
2 60.23 1.75 24.23–94.23 D2Mit46 Femur vBMD B6 B6 CAST
(36) F( M? )
2 69.80 2.72 62.70–102.29 D2Mit166 Femur aBMD DBA B6 DBA
(56,57) F
2 77.81 2.15 1.81–82.95 D2Mit285 Femoral mid vBMD SJL MRL SJL
(32,33) F( M? )
2 79.42 4.04 73.42–88.99 D2Mit48 Femur vBMD C3H B6 C3H
(34) F( M? )
2 85.81 2.29 51.81–100.49 D2Mit411 Femoral mid vBMD RF NZB RF
(31) F( M? )
2 87.22 2.57 66.23–102.23 D2Mit413 Femur aBMD B6 B6 DBA
(30) F( M? )
2 87.22 2.57 66.23–102.23 D2Mit413 Femur aBMD B6 B6 DBA
(30) F( M? )
2 97.81 2.63 27.81–100.49 D2Mit148 Femoral midcort vBMD RF NZB RF
(31) F( M? )
3 3.96 2.83 1.96–37.96 D3Mit23 Femur vBMD CAST B6 CAST
(36) F( M? )
3 14.82 4.95 10.82–24.82 D3Mit203 Femoral mid vBMD RF NZB RF
(31) F( M? )
3 34.85 2.55 3.55–51.21 rs3714671 Femur aBMD C3H B6 C3H
(29) F&M
3 38.19 2.74 24.01–62.01 D3Mit40 Femur aBMD B6 B6 DBA
(56,57) F&M
3 38.19 3.93 32.01–52.01 D3Mit40 Whole-body aBMD B6 B6 DBA
(56,57) F&M
3 68.85 4.00 54.85–72.85 D3Mit127 Femur vBMD DBA B6 DBA
(30) F( M? )
4 44.43 2.96 26.43–56.43 D4Mit9 Femoral mid vBMD MRL MRL CAST
(39) F&M
4 48.04 15.07 45.76–54.04 D4Mit187 Vertebral vBMD C3H B6 C3H
(34) F( M? )
4 52.04 22.94 50.04–66.04 D4Mit124 Femur vBMD C3H B6 C3H
(34) F( M? )
4 62.14 2.82 48.14–66.26 D4Mit204 Femoral mid vBMD SJL MRL SJL
(32,33) F( M? )
4 63.26 12.22 63.26–66.01 rs3023007 Femur aBMD C3H B6 C3H
(29) F&M
4 63.60 2.64 37.60–69.05 D4Mit251 Femur vBMD RF NZB RF
(31) F( M? )
4 65.60 4.28 51.60–69.05 D4Mit251 Femoral cort vBMD RF NZB RF
(31) F( M? )
4 68.43 3.04 54.43–82.64 D4Mit308 Whole-body aBMD 129 B6 129
(35) F( M? )
4 69.05 4.32 53.60–69.05 D4Mit251 Femoral midcort vBMD RF NZB RF
(31) F( M? )
4 71.60 2.45 57.60–86.17 D4Mit68 Femur vBMD B6 B6 CAST
(36) F( M? )
4 73.41 4.94 70.22–78.22 D4Mit48 Femur aBMD DBA B6 DBA
(56,57) F&M
4 73.41 10.94 70.22–76.22 D4Mit48 Whole-body aBMD DBA B6 DBA
(56,57) F&M
5 41.43 4.26 11.43–49.43 D5Mit10 Femoral mid vBMD MRL MRL CAST
(39) F
5 41.43 5.06 33.43–55.43 D5Mit112 Femur vBMD B6 B6 CAST
(36) F( M? )
5 50.62 3.47 2.62–56.62 D5Mit10 Femoral midcort vBMD RF NZB RF
(31) F( M? )
5 50.64 2.62 2.621–68.62 D5Mit10 Femoral mid vBMD RF NZB RF
(31) F( M? )
5 77.43 2.44 3.43–86.57 D5Mit284 Vertebral aBMD SM NZB SM
(58) F&M
6 27.38 3.88 23.81–43.81 D6Mit384 Whole-body aBMD B6 B6 CASA
(52) F&M
6 29.81 4.03 25.40–57.81 D6Mit124 Femur vBMD B6 B6 C3H
(34) F( M? )
6 31.81 3.61 17.81–41.81 D6Mit209 Vertebral aBMD 129 B6 129
(35) F( M? )
(Continued)
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Chr
Peak
(cM)
LOD
score
Confidence
interval (cM) Peak marker Phenotype
a
High
allele
Cross
(reference)
Gender
specific
b
6 31.81 4.18 15.81–41.81 D6Mit209 Whole-body aBMD 129 B6 129
(35) F( M? )
6 52.15 4.41 26.15–66.15 D6MIT256 Whole-body aBMD MRL MRL SJL
(32,33) F( M? )
6 53.81 3.95 49.81–73.81 D6Mit55 Femur aBMD B6 B6 DBA
(56,57) M
6 63.74 4.21 35.74–71.74 D6Mit25 Femur aBMD B6 B6 DBA
(30) F( M? )
6 69.74 2.57 27.74–77.70 D6Mit198 Femur vBMD DBA B6 DBA
(30) F( M? )
6 71.81 2.25 21.81–77.70 D6Mit15 Whole-body aBMD DBA B6 DBA
(56,57) F&M
6 75.81 1.97 1.81–77.70 D6Mit15 Vertebral vBMD B6 B6 C3H
(34) F( M? )
6 77.64 2.08 15.81–77.64 D6Mit14 Femoral mid vBMD NZB NZB RF
(31) F( M? )
7 13.94 7.53 11.94–25.94 D7Mit114 Femur aBMD DBA B6 DBA
(56,57) F&M
7 15.42 3.44 9.94–23.94 D7Mit114 Whole-body aBMD DBA B6 DBA
(56,57) F&M
7 16.94 2.93 8.83–43.97 rs4226499 Femur aBMD C3H B6 C3H
(29) F&M
7 20.71 2.21 2.71–31.44 D7Mit80 Femoral mid vBMD B6 B6 DBA
(30) F( M? )
7 22.02 2.84 2.02–62.02 D7Mit310 Whole-body aBMD CASA B6 CASA
(52) F&M
7
c 33.16 4.16 8.83–43.97 rs3688333 Femur aBMD C3H B6 C3H
(29) F&M
7 47.86 2.90 35.86–69.86 D7Mit300 Vertebral aBMD B6 B6 129
(35) F( M? )
7 69.46 4.84 47.46–77.87 D7Mit238 Vertebral vBMD B6 B6 C3H
(34) F( M? )
7 74.71 4.52 54.71–84.71 D7Mit358 Femoral mid vBMD NZB NZB RF
(31) F( M? )
7 76.71 5.16 68.71–82.71 D7Mit358 Femur vBMD NZB NZB RF
(31) F( M? )
8 18.89 1.98 7.59–49.59 D8Mit4 Femur vBMD C3H B6 C3H
(34) F( M? )
8 48.52 2.79 38.52–66.52 D8Mit211 Whole-body aBMD B6 B6 CASA
(52) F&M
8 50.75 3.81 20.75–58.75 D8Mit113 Femur aBMD DBA B6 DBA
(56,57) F&M
8 74.46 2.27 12.14–74.46 D8Mit42 Whole-body aBMD SM NZB SM
(58) F&M
9 32.76 2.68 12.46–44.46 D9Mit207 Whole-body aBMD MRL MRL SJL
(32,33) F( M? )
9 35.80 2.24 23.80–47.80 D9Mit129 Femoral mid vBMD CAST MRL CAST
(39) F&M
9 42.32 3.82 36.46–53.48 D9MIT263 Femoral mid vBMD MRL MRL SJL
(32,33) F( M? )
9 44.24 4.83 22.24–52.24 D9Mit196 Vertebral vBMD B6 B6 C3H
(34) F( M? )
9 46.08 12.54 42.08–50.08 D9Mit196 Vertebral aBMD NZB NZB SM
(58) F
9 48.08 9.90 30.08–52.08 D9Mit196 Whole-body aBMD NZB NZB SM
(58) F
9 48.24 2.35 22.24–66.24 D9Mit196 Femur vBMD B6 B6 C3H
(34) F( M? )
9 49.80 5.49 45.80–61.80 D9Mit10 Femur aBMD B6 B6 DBA
(56,57) F&M
9 63.8 2.34 19.80–71.49 D9Mit18 Femoral mid vBMD NZB NZB RF
(31) F( M? )
9 66.48 2.95 42.48–71.32 D9Mit311 Whole-body aBMD B6 B6 CASA
(52) M
9 71.49 6.50 63.80–71.49 D9Mit18 Femur vBMD NZB NZB RF
(31) F( M? )
10 2.53 2.58 2.53–58.53 D10Mit75 Whole-body aBMD B6 B6 DBA
(56,57) F&M
10 5.03 3.12 3.03–23.03 D10Mit28 Femur vBMD CAST B6 CAST
(36) F( M? )
10 25.91 3.10 5.91–39.91 D10Mit31 Femoral mid vBMD CAST MRL CAST
(39) F&M
10 51.66 2.50 33.66–61.58 D10Mit95 Vertebral vBMD C3H B6 C3H
(34) F( M? )
10 54.72 2.95 27.31–66.75 rs3672179 Femur aBMD B6 B6 C3H
(29) F&M
10 62.53 2.39 34.53–72.31 D10Mit162 Femur aBMD B6 B6 DBA
(56,57) M
10 66.75 2.30 7.27–66.75 D10Mit14 Femoral mid vBMD NZB NZB RF
(31) F( M? )
11 33.04 6.20 24.20–37.81 rs4228731 Femur aBMD C3H B6 C3H
(29) M
11 34.70 6.81 26.70–46.70 D11Mit242 Femur vBMD C3H B6 C3H
(34) F( M? )
11 38.70 7.19 26.70–42.88 D11Mit30 Femur vBMD RF NZB RF
(31) F( M? )
11 44.7 8.49 36.70–60.70 D11Mit30 Femoral mid vBMD RF NZB RF
(31) F( M? )
11 51.34 8.23 46.44–58.44 D11Mit355 Whole-body aBMD B6 B6 DBA
(56,57) F&M
11 60.70 2.82 4.70–74.70 D11Mit126 Femoral midcort vBMD RF NZB RF
(31) F( M? )
11 70.70 2.92 34.70–75.93 D11Mit301 Vertebral vBMD C3H B6 C3H
(34) F( M? )
12 2.94 4.60 2.94–24.94 D12Mit215 Femur vBMD B6 B6 C3H
(34) F( M? )
12 5.52 2.91 5.52–33.52 D12Mit182 Femoral mid vBMD SJL MRL SJL
(32,33) F( M? )
12 30.20 3.52 15.52–47.52 D12Mit201 Femur vBMD NZB NZB RF
(31) F( M? )
12 33.52 6.32 25.52–57.52 D12Mit60 Whole-body aBMD NZB NZB SM
(58) F&M
12 43.52 5.24 31.52–69.52 D12Mit60 Vertebral aBMD NZB NZB SM
(58) F&M
12 60.56 2.60 2.94–60.56 D12Mit79 Vertebral vBMD C3H B6 C3H
(34) F( M? )
(Continued)
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Chr
Peak
(cM)
LOD
score
Confidence
interval (cM) Peak marker Phenotype
a
High
allele
Cross
(reference)
Gender
specific
b
13 5.08 3.33 3.08–51.11 D13Mit205 Femur vBMD CAST B6 CAST
(36) F( M? )
13 6.05 2.18 6.05–54.05 D13Mit303 Whole-body aBMD DBA B6 DBA
(56,57) F&M
13 28.99 2.81 18.99–50.99 D13Mit13 Vertebral vBMD B6 B6 C3H
(34) F( M? )
13 30.06 11.19 26.99–32.99 D13Mit13 Femur vBMD C3H B6 C3H
(34) F( M? )
13 41.92 4.08 25.92–55.92 D13Mit202 Whole-body aBMD MRL MRL SJL
(32,33) F( M? )
13 46.45 5.24 38.45–62.45 D13Mit191 Whole-body aBMD B6 B6 CASA
(52) F&M
13 57.92 2.24 15.92–65.43 D13Mit204 Femoral mid vBMD NZB NZB RF
(31) F( M? )
13 65.17 2.57 30.31–67.21 rs3656262 Femur aBMD C3H B6 C3H
(29) F&M
14 8.03 2.55 6.03–59.53 D14Mit132 Femoral mid vBMD MRL MRL SJL
(32,33) F( M? )
14 18.67 3.04 6.86–24.60 rs3709612 Femur aBMD C3H B6 C3H
(29) F&M
14 34.73 4.66 28.73–50.73 D14Mit160 Femur vBMD C3H B6 C3H
(34) F( M? )
14 35.08 2.50 25.08–63.08 D14Mit142 Femur aBMD DBA B6 DBA
(56,57) F&M
14 42.73 4.58 32.73–55.83 D14Mit160 Vertebral vBMD C3H B6 C3H
(34) F( M? )
14 56.16 3.66 31.53–63.53 D14Mit170 Femur vBMD CAST B6 CAST
(36) F( M? )
14 57.08 2.05 13.08–59.53 D14MIT75 Vertebral aBMD 129 B6 129
(35) F( M? )
15 3.80 3.32 1.80–29.80 D15Mit13 Femur aBMD DBA B6 DBA
(30) F( M? )
15 3.80 2.96 1.80–19.80 D15Mit13 Femur aBMD DBA B6 DBA
(30) F( M? )
15 13.02 2.65 3.96–26.07 D15Mit111 Vertebral vBMD B6 B6 C3H
(34) F( M? )
15 21.96 2.24 17.41–47.41 D15Mit26 Vertebral aBMD NZB NZB SM
(58) F&M
15 22.92 2.31 9.84–55.99 D15MIT115 Femoral mid vBMD MRL MRL CAST
(39) F&M
15 33.84 3.20 16.82–51.84 D15Mit63 Femur aBMD B6 B6 DBA
(56,57) F&M
15 34.16 4.54 29.80–47.80 D15Mit29 Femur vBMD B6 B6 CAST
(36) F( M? )
15 35.84 3.34 22.92–49.84 D15MIT159 Whole-body aBMD MRL MRL CAST
(39) F&M
15 37.85 8.28 29.84–53.94 D15Mit2 Whole-body aBMD B6 B6 CASA
(52) F&M
15 38.67 3.88 25.84–47.84 D15Mit189 Whole-body aBMD B6 B6 DBA
(56,57) M
16 29.33 4.04 17.33–45.33 D16Mit12 Femur vBMD C3H B6 C3H
(34) F( M? )
17 4.11 2.46 2.11–28.11 D17Mit164 Vertebral vBMD B6 B6 C3H
(34) F( M? )
17 6.92 2.54 4.92–28.93 D17Mit143 Whole-body aBMD B6 B6 DBA
(56,57) F&M
17 16.93 4.16 4.92–34.92 D17Mit175 Femoral mid vBMD MRL MRL SJL
(32,33) F( M? )
17 19.66 5.00 12.93–22.93 D17Mit176 Whole-body aBMD MRL MRL SJL
(32,33) F( M? )
17 46.29 3.38 32.29–52.25 D17Mit39 Whole-body aBMD MRL MRL CAST
(39) F&M
17 52.11 3.12 42.11–55.02 D17Mit155 Femur vBMD C3H B6 C3H
(34) F( M? )
17 55.93 2.27 43.93–60.67 D17Mit123 Femoral midcort vBMD NZB NZB RF
(31) F( M? )
18 15.02 3.64 13.02–39.02 D18Mit34 Femoral mid vBMD MRL MRL SJL
(32,33) F( M? )
18 24.64 8.11 20.46–28.46 D18Mit36 Vertebral vBMD C3H B6 C3H
(34) F( M? )
18 28.46 17.19 22.46–34.46 D18Mit36 Femur vBMD C3H B6 C3H
(34) F( M? )
18 40.14 2.83 21.02–43.02 D18MIT50 Vertebral aBMD 129 B6 129
(35) F( M? )
18 43.21 3.88 28.09–51.07 rs3669949 Femur aBMD C3H B6 C3H
(29) F&M
18 54.04 4.88 40.04–57.53 D18Mit4 Femoral midcort vBMD RF NZB RF
(31) F( M? )
18 54.04 5.49 42.04–57.53 D18Mit4 Femoral midcort vBMD RF NZB RF
(31) F( M? )
18 56.04 2.92 40.04–57.53 D18Mit4 Femur vBMD RF NZB RF
(31) F( M? )
18 57.02 3.32 33.02–57.53 D18MIT43 Whole-body aBMD 129 B6 129
(35) F( M? )
18 57.53 1.75 14.53–57.53 D18Mit6 Femur vBMD CAST B6 CAST
(36) F( M? )
19 11.04 1.58 3.04–43.04 D19Mit32 Femur vBMD CAST B6 CAST
(36) F( M? )
19 12.34 3.24 4.34–28.34 D19Mit16 Femur aBMD DBA B6 DBA
(56,57) F
19 12.40 2.08 10.40–40.53 D19Mit61 Femur vBMD C3H B6 C3H
(34) F( M? )
19 29.82 2.34 15.82–39.82 D19Mit11 Vertebral aBMD SM NZB SM
(58) F&M
19 43.33 2.46 23.33–56.28 D19Mit53 Femoral mid vBMD SJL MRL SJL
(32,33) F( M? )
X 26.73 4.78 10.73–42.73 DXMit144 Femur aBMD B6 B6 DBA
(56,57) F&M
aMidshaft (mid), cortical (cort).
bFemale (F), Male (M); no data available for males in that cross (?).
cCross-direction-specific, only seen in C3H B6 cross direction.
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Fig. 1. Mouse BMDQTLs comparedwithhuman GWAS loci.BMD QTLs for femoral(purple), whole-body(blue), andvertebral(green) BMD arepresented to
scale on the left side of each chromosome. Each white space along the chromosomal axis represents 10 cM. Each QTL is presented such that the vertical
bar representing the QTL starts at the upper limit of the 95% confidence interval (CI) and extends to the lower end of the CI. The peak for the QTL is
denoted by a black bar within the CI span. The human GWAS loci, as lifted over to the mouse genome coordinates, are represented as red triangles to the
right of each chromosome.
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these loci are within 5 cM of the peak of mouse QTL.
GWSlociforBMDalsohavebeenindentifiedinsmallercohorts
independent of the GEFOS meta-analysis GWAS. While these
other cohorts did identify some of the same loci as were found in
the GEFOS study, eight additional GWS loci have been described.
Deng and colleagues have identified six loci in a small cohort
of U.S. Caucasians.
(26,27) All six of these loci mapped within the CI
of a mouse BMD QTL. Three of these six loci loci mapped to
within 2cMofthe peakfora mouseQTL, andafourth mapped to
within 3.1 cM (Table 3). Two more BMD loci were identified in
largestudyofKoreanindividuals(KoGESStudycohorts).
(25)While
both these GWS loci were found within the CIs of mouse BMD
QTLs, neither of these loci mapped in close proximity to a mouse
QTL peak. Inthe KoGES Study, BMD ofthe distal radius and ofthe
midshaft of the tibia was measured,
(26) not BMD of the femoral
neck and lumbar spine, as was measured in the other two GWAS.
Three of the KoGES loci were confirmed in the GEFOS Study
(human chromosome 7, rs1721400, human chromosome 7,
rs6974574, and human chromosome 13, rs9525667) and may
represent loci controlling BMD ‘‘globally.’’ The other two KoGES
loci may be more site-specific regulators of BMD, and thus it may
not be straightforward to compare these loci with the other
human loci and with the spinal, femoral, and whole-body BMD
QTLs in the mouse.
Confirmation of Mef2c as a candidate gene for BMD
In the GEFOS Study, the most significant SNP at 5q14 for femoral
BMD was located in an intergenic region approximately 200kb
distal to the MEF2C coding sequence. All the surrounding SNPs
with a p value of less than 1 10
 8 also were located in this
Table 3. Comparison of Human GWAS Loci With Mouse QTLs
Human Mouse
In mouse
QTL?
Nearest mouse
QTL (cM) Study (reference) SNP ID
a Chr. Bp Chr. Bp cM
GEFOS
(3) rs7524102 1 22,570,784 4 136,661,533 69.3 Yes 0.2
rs6426749 1 22,583,810 4 136,657,367 69.3 Yes 0.2
rs1430742 1 68,407,413 3 159,552,734 82.7 No
rs2566755 1 68,407,728 3 159,552,348 82.7 No
rs11898505 2 54,537,811 11 30,167,162 17.7 Yes 15.3
rs87938 3 41,112,426 9 120,766,377 72.0 Likely 1.0
rs1471403 4 88,994,017 5 104,773,742 50.7 Yes 0.1
rs1366594 5 88,411,567 13 83,453,756 43.7 Yes 1.8
rs2941740 6 152,051,081 10 5,736,893 2.1 Likely 1.0
rs2504063 6 152,132,150 10 5,667,438 2.1 Likely 1.0
rs1524058 7 38,102,552 13 19,538,734 6.9 Yes 0.9
rs4729260 7 95,955,604 6 6,305,527 2.5 Yes 24.9
rs7781370 7 95,971,217 6 6,323,120 2.5 Yes 24.9
rs2062377 8 120,076,351 15 54,166,754 21.1 Yes 0.8
rs11995824 8 120,081,631 15 54,179,867 21.1 Yes 0.8
rs7117858 11 15,650,788 7 122,379,000 60.9 Yes 8.6
rs16921914 11 31,167,097 2 105,937,807 55.5 Yes 2.3
rs7932354 11 46,678,547 2 91,490,042 50.6 Yes 5.9
rs599083 11 67,948,672 19 3,604,166 3.3 Yes 7.7
rs2016266 12 52,013,972 15 102,194,741 57.5 No
rs9533090 13 41,849,199 14 78,848,972 41.4 Yes 1.3
rs10048146 16 85,267,911 8 123,719,142 70.4 Yes 4.1
rs228769 17 39,548,461 11 102,084,442 66.0 Yes 4.7
rs9303521 17 41,160,727 11 103,944,446 67.7 Yes 3.0
rs884205 18 58,205,587 1 107,744,514 49.7 Yes 1.9
U.S. Caucasians
(26,27) rs17131547 1 91,983,358 5 107,591,590 52.1 Yes 1.5
rs4276378 5 7,297,491 13 69251843 35.6 Yes 5.5
rs1823926 5 119,882,620 18 51320749 28.0 Yes 0.4
rs11239762 10 42,582,267 6 118362999 55.9 Yes 2.1
rs12437971 15 98,662,088 7 74,018,517 36.3 Yes 3.1
rs16945612 16 75,986,223 8 116,327,071 60.1 Yes 9.4
KoGES
(25) rs7776725 7 120,820,107 6 22,304,412 9.3 Yes 18.1
rs550677 12 124,376,759 5 126,093,513 64.3 Yes 13.1
aSome peaks in the GEFOS Study were denoted by two-peak SNPs. For consistency, both GEFOS peak SNPs are presented. Peaks in the U.S. Caucasians
and KoGES studies that were within 1 Mb of peaks in the GEFOS Study are not included.
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disequilibrium with SNPs in the coding region of MEF2C.
(3)
Furthermore, 5q14 is a novel GWS locus for BMD and has not
been replicated thus far in an independent cohort. Thus we
wished to substantiate MEF2C as a gene that should be further
examined for genetic association with BMD. This GWS locus in
mice is located between two QTL peaks for aBMD that had been
mapped in MRL SJL and B6 CASA (Fig. 2). We used block
haplotyping to determine if Mef2c could be a candidate for these
twomouseQTLs.Inshort,338 uniqueRefseq genesfallwithin the
confidence interval for the MRL SJL QTL, 186 in the B6 CASA
QTL, with 153 genes falling in the region wherein the CI for these
two QTLs overlap. By block haplotyping, we reduced the list of
possible candidate genes to six genes, including Mef2c (Fig. 2).
We repeated the haplotyping without the SJL/J equal to the
CASA/RkJterm andconfirmed thatMef2c should beconsidered a
candidate for these QTLs in mice.
Discussion
Impact of the new genetic map on studies based on
congenic mice
A congenic is a strain of mice wherein the alleles for specific
genetic regions from one inbred strain (the donor strain) are
moved over to another inbred strain (the background strain)
using a backcross-breeding scheme. Congenic mice are useful
in that they can confirm that the alleles of the donor strain at
that locus change the phenotype of interest relative to the
background strain. Congenics are powerful tools to examine the
basic biology underlying a QTL. Congenic mice are genotyped to
ensure that the genetic region of interest has been carried over
from the donor strain onto the background strain. It is possible
to make a congenic region for the ‘‘wrong’’ genetic location
(ie, somewhere other than for which the data suggest there is
a QTL) and still get a phenotype. QTL analysis is designed to
identify association between a genotype and phenotype that
achieves some level of statistical significance. Not every locus is
going to be identified in a given F2 cross, especially if that cross
contained only a small number of animals. Congenic studies still
in the planning stages could be affected by our finding in that
thegeneticlocationoftheQTLhas‘‘moved.’’However,aslongas
theinvestigatorusesthesamemarkersfoundtobeclosesttothe
QTL peak and the associated flanking markers used in the F2
analysis to make the congenic, the correct congenic piece from
the donor strain will be carried over.
Concordant QTLs
One of the main purposes of our study was to provide a listing of
BMD QTLs, all mapped using a common genetic map and a
common mapping algorithm, such that QTLs from different
crosses could be compared with ease and confidence.
Furthermore, it has long been thought that there should be
concordance in peak location for QTLs identified by different
crosses. However, because of discrepancies in the genetic map
and in the various calculation algorithms, grouping QTL peaks
based on literature-reported peak location was at best tricky and
at worse misleading. In this recalculation study, we were not
hindered by these obstacles, and we therefore can group QTLs
with increased confidence. Indeed, there are clear examples
where QTLs identified by various groups may be one and the
same. For example, on chromosome 18 we report 10 different
QTLs identified in six different crosses (Table 2). Based on peak
location, our data suggest that there may be only 4 unique QTLs,
not 10. The first of these QTLs is supported only by a single cross,
with a peak at 15 cM.
(32,33) The second QTL is also supported by
only a single cross, the B6 C3H cross generated by Beamer and
colleagues,
(34) but the peaks for vertebral vBMD (at 25 cM) and
for femoral vBMD (at 29 cM) are likely one QTL regulating global
BMD.Thepeaklocation forthisQTLmapstothesamelocation as
a GWAS peak identified by Deng and colleagues.
(27) The third
QTL group is supported by two different crosses and is
represented by a QTL mapped in B6 129
(35) at 40 cM and
by a second QTL mapped in the B6 C3H cross generated by
Farber and colleagues,
(29) with a peak at 43 cM. The fourth and
final QTL is the most interesting in that it was identified in three
crosses: B6 CAST
(36) at 58 cM, B6 129
(35) at 56 cM, and
for three bone phenotypes in NZB RF
(31) at peaks 54, 54, and
56 cM.
A traditional F2 cross has poor mapping resolution, so it is
difficult to say with confidence how far apart two QTLs can be
and still be caused by the same genetic entity. Furthermore,
concordant peak location does not mean that the two QTLs
share the same genetic cause. There are statistical tests such as
biallelic combining of crosses
(8) that can be done to interrogate
whether two crosses share a QTL or if that QTL is cross-specific.
Performing such analysis for all possible shared QTLs is beyond
the scope of this study.
38 cM 
72.1 Mb 
55.9 cM 
104.0 Mb 
Human rs1524058 GWS Locus 
338 genes 
186 genes 
MRLxSJL
B6xCASA
153 genes 
Mef2c
Acot12
Ssbp2 Arsb
Cmya5
Mast4
Chr 13 
(cM)
Fig. 2. Confirmation of Mef2c as candidate gene for BMD on mouse
chromosome 13. A GWS locus was identified on human chromosome 7
with a peak at rs1524058. The GWS locus is found in close proximity to
two BMD QTLs in the mouse that were identified in MRL SJL and
B6 CASA. The confidence intervals (CI) for these two mouse QTLs
overlap for the interval from 38 to 55.9 cM (72.1 to 104 Mb). A total
of338RefseqgenesarelocatedwithintheMRL SJL CI,186geneswithin
the B6 CASA CI, and 153 genes are located where the CI for these two
QTLs overlap. Using block haplotyping, we were able to eliminate all but
sixofthesegenesascandidatesforthisQTL.ThegeneMef2c(blackbox)is
the gene closest to the human GWS locus, and it remained a candidate
after haplotyping.
NEW MOUSE GENETIC MAP IMPROVES BMD QTL MAPPING Journal of Bone and Mineral Research 1817Differences among data sets
While this study does reconcile differences in mapping
algorithms and genetic maps, fundamental differences in study
design used bydifferent investigators also should be considered.
The mice examined in four of the crosses had been fed a high-fat
diet prior to obtaining the phenotype data (Table 1). A high-fat
diet may alter the BMD, and it is likely that gene-by-dietary-fat
interaction(s) may affect BMD as well.
(37) Earlier we discuss an
example for chromosome 18. The second chromosome 18 QTL
grouping is solely represented by B6 C3H. The third bin also
contains a B6 C3H femoral BMD QTL, but in this case, the mice
fromthemappingcrosshadbeenfedahigh-fatdiet.Infact,both
crosses inthisthird binofQTLshadbeenfed ahigh-fatdiet. Thus
the use of a different diet likely suggests that there are indeed
two distinct B6 C3H BMD QTLs on chromosome 18 and that
this finding is not a function of poor mapping resolution.
The age of the mice measured for BMD does differ among the
11 data sets analyzed. Peak BMD in mice is obtained at or around
16 weeks of age for most inbred strains.
(38) For the majority of
data sets, BMD was measured at or near to this age of peak BMD.
It must be noted that the mice in the MRL CAST
(39) and
MRL SJL
(40) crosses were substantially younger than 16 weeks
of age, and for one of the two B6 DBA crosses, the mice were
much older (Table 1). This age difference may explain the
differences in QTLs identified in the two B6 DBA crosses.
For each data set, BMD was obtained using a slightly different
protocol. In essence, BMD can be broken down into two types:
volumetric BMD (vBMD), as obtained by a computed tomo-
graphicapproach,andarealBMD(aBMD),forwhichtheBMDwas
obtained by densitometric analysis of plain-film X-rays or by
using a dual-energy X-ray absorptiometer. The BMD data also
can be classed by anatomic site of measure: whole-body scans of
the head, femur, or vertebra. We list the type of BMD phenotype
data for each cross in Table 1. For presentation purposes, we
have subdivided the QTLs based on the anatomic site at which
BMD was obtained (Fig. 1), but we list the exact BMD phenotype
for each QTL in Table 2. Two QTLs with concordant peak
locations but for a different anatomic site may well be caused by
the same genetic entity, as is suggested earlier by the femoral
and vertebral BMD QTLs on chromosome 18 mapped in the
B6 C3H data set from Beamer and colleagues. Other studies,
however, have suggested intrinsic differences in bone physiol-
ogy at different anatomic sites.
(41) Thus we have subdivided the
QTLs by anatomic site.
Comparison with human BMD loci
Traditional QTLs for BMD have been mapped in humans in many
small studies.
(42) Meta-analyses of the human BMD QTLs have
been done to improve the power to detect these QTLs.
(43,44) In a
meta-analysis of genetic loci, the genome is divided into equal-
sized bins, and bins with significant linkage to the phenotype
are reported. While a valid approach to overcome small-sample-
size issues, meta-analysis loci cannot be lifted over easily from
one species to another. By definition, the meta-analysis bins are
large, and no specific peak location within that bin is calculated.
Thus a single-human-genome bin may be homologous to
multiple mouse chromosomal regions. For this reason, it is
impractical to compare the mouse QTLs with the human BMD
meta-analysis results, and we have therefore chosen to compare
the mouse QTLs with the human loci mapped in GWAS. The
human GWAS loci are sufficiently narrow that they can be lifted
over to a single-mouse-chromosomal location, and the GWAS
loci reach a genome-wide significant threshold.
There are limitations of the GWAS studies done to date in
humans. First of all, no vBMD QTLs have been mapped; only
aBMD data are available. Second, sex specificity of the QTLs
has not been considered. Third, the X chromosome has not
been considered in the GWAS studies for bone. Fourth, GWAS
studies consider only the common SNPs (usually minor allele
frequency>1%).
(4) Fifth, large GWAS studies for some ethic
groups are lacking. Sixth, the highly significant human GWS loci
explain only a fraction of the variance found in aBMD in
humans.
(3) In this study we describe 155 QTLs for mice. As stated
earlier, it would be beyond the scope of this article to statistically
assess how many of these loci are truly concordant. That said,
we estimate that these 155 loci can be collapsed into about
85 distinct loci for BMD identified to date in the mouse. The
GWAS studiesprovideuswithacandidategene(s)totestforonly
30% of these QTLs. Finding the genes underlying the remaining
70% of the mouse loci and then testing those genes in humans
could be one way of trying to capture some of the ‘‘missing
variation’’ or so-called genetic dark matter endemic in GWAS
studies.
Work with congenic strains has suggested that there are at
least five distinct QTLs on mouse chromosome 1: 37 to 41 cM, 68
to 70cM, 79to80 cM, at84 cM,and90 to97 cM,
(45–48) inaddition
to the B6 DBA peak at 51.7 cM for femoral aBMD. Only the
B6 DBA peak is likely explained by the GWAS loci identified to
date. Edderkaoui and colleagues have determined that Duffy
blood group, chemokine receptor (Darc), likely explains at least
one ofthese QTL,
(49) butthis genehasnot yetbeen examinedfor
association with BMD in humans. Lipoxygenase 15 (Alox15) was
identified as a QTL candidate gene for mouse chromosome 11.
This gene was found to be associated with BMD in Chinese
women,
(50) an ethnic group not yet well represented by a large
GWAS. These two examples demonstrate that the mouse can
be used to find genes that regulate BMD outside the GWAS
loci known to date.
While the resolution of mapping in a GWAS is far superior
to the more traditional QTL-based mapping in humans,
identification of a GWS locus does not necessary equal
immediate identification of a causative gene.
(5) Approximately
half the human GWS loci for BMD fall in intergenic regions of the
genome. Still more GWS loci fall in gene-dense regions, wherein
there is more than one candidate gene for the locus.
(3) By
examining concordant QTLs in mice, we can better resolve these
more enigmatic GWS loci to an actual gene or causal variant and
make models for the study of the biologic mechanism by which
the locus affect BMD. For example, the peak SNP and all the
subsignificant supporting SNPs for the human chromosome
5 rs1366594 GWS locus are located in an intergenic region near
to the human MEF2C gene.
(3) Expression of Mef2c has been
demonstratedinbothosteoblastsandosteocytesinrodents,and
Mef2c is thought to regulate Sost expression, proving a role for
this gene in bone biology.
(51) Using block haplotyping, we were
1818 Journal of Bone and Mineral Research ACKERT-BICKNELL ET AL.able to confirm that this gene should be considered a candidate
gene for this QTL. Moreover, a potential splice-site polymorph-
ism has been identified in this gene in several strains of
mice (rs47941354), which may be the underlying causal variant.
Body weight and/or body size can influence BMD. Vitarius and
colleagues, when originally analyzing the B6 CASA cross,
identified a body-weight QTL on chromosome 13.
(52) It is
possible that Mef2c affects BMD by altering body mass. QTLs for
forelimb muscle mass and body length also were examined in
the MRL SJL cross, but no QTLs on chromosome 13 for these
two phenotypes are reported.
(53) This lack of a lean-mass QTL in
the MRL SJL cross does not rule out a possible role for Mef2c in
the modulation of fat mass or total body weight to affect bone
mass. This possible interaction between body weight and fat
mass requires further study. Thus studies in mice can be used to
confirm novel GWAS loci, can be used to identify actual causal
polymorphisms, and can be used to establish the role of the
candidate gene in bone biology.
Conclusion
In summary, we remapped the QTLs from 11 mouse mapping
crosses using a single mapping study design and using a single
corrected version of the mouse genetic map. Our results
demonstrate that the BMD QTLs found in different crosses bin
together in many instances across the genome, validating the
use of such QTL narrowing techniques as combined cross-
analysis and block haplotyping. We have shown that QTLs
mapped with this new version of the mouse genetic map do
agree very well with human BMD GWS loci. With the newly
available high-resolution GWAS mapping in humans and our
improved QTL mapping in mouse, we believe that this is an
opportune time for a renewed effort by the genetics community
to identify the causal variants regulating BMD using a synergistic
mouse-human approach.
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